JP2003514565A - 非分裂細胞を不死化する能力をもつベクター及び前記ベクターで不死化された細胞 - Google Patents

非分裂細胞を不死化する能力をもつベクター及び前記ベクターで不死化された細胞

Info

Publication number
JP2003514565A
JP2003514565A JP2001539890A JP2001539890A JP2003514565A JP 2003514565 A JP2003514565 A JP 2003514565A JP 2001539890 A JP2001539890 A JP 2001539890A JP 2001539890 A JP2001539890 A JP 2001539890A JP 2003514565 A JP2003514565 A JP 2003514565A
Authority
JP
Japan
Prior art keywords
vector
cell
cells
molecule
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001539890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514565A5 (enExample
Inventor
オチオドロ，テレサ
サルモン，パトリック
トローノ，ディディエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Geneva filed Critical University of Geneva
Publication of JP2003514565A publication Critical patent/JP2003514565A/ja
Publication of JP2003514565A5 publication Critical patent/JP2003514565A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001539890A 1999-11-25 2000-11-24 非分裂細胞を不死化する能力をもつベクター及び前記ベクターで不死化された細胞 Pending JP2003514565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99123498.0 1999-11-25
EP99123498A EP1103615A1 (en) 1999-11-25 1999-11-25 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
PCT/EP2000/011723 WO2001038548A2 (en) 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Publications (2)

Publication Number Publication Date
JP2003514565A true JP2003514565A (ja) 2003-04-22
JP2003514565A5 JP2003514565A5 (enExample) 2008-01-24

Family

ID=8239461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001539890A Pending JP2003514565A (ja) 1999-11-25 2000-11-24 非分裂細胞を不死化する能力をもつベクター及び前記ベクターで不死化された細胞

Country Status (6)

Country Link
US (1) US20090142841A1 (enExample)
EP (2) EP1103615A1 (enExample)
JP (1) JP2003514565A (enExample)
AU (1) AU2667901A (enExample)
CA (1) CA2389667A1 (enExample)
WO (1) WO2001038548A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528567A (ja) * 2008-07-21 2011-11-24 タイガ バイオテクノロジーズ，インク． 分化無核細胞、及び該無核細胞の作成方法
JP2013017486A (ja) * 2005-10-18 2013-01-31 National Jewish Health 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
JPWO2022097716A1 (enExample) * 2020-11-06 2022-05-12
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680613A1 (en) 2007-03-13 2008-09-18 National Jewish Medical And Research Center Methods for generation of antibodies
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2501801A1 (en) 2009-11-18 2012-09-26 The Board of Trustees of The Leland Stanford Junior University Methods of inducing tissue regeneration
JP5863338B2 (ja) * 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
ES2634457T3 (es) 2011-10-18 2017-09-27 Univercell Biosolutions Producción de una línea de células beta humanas a partir de un páncreas postnatal temprano
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
CN103468746B (zh) * 2013-09-28 2015-03-04 青岛麦迪赛斯生物科技有限公司 一种肿瘤细胞系的构建方法
CA3024296A1 (en) 2016-05-11 2017-11-16 Animal Cell Therapy - Act Production of a canine beta cell line from an immature pancreas
EP3707243A1 (en) 2017-11-08 2020-09-16 Animal Cell Therapy - Act Production of canine pancreatic islets from an immature pancreas
CN111154807B (zh) * 2020-01-17 2023-03-24 山东农业大学 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法
WO2022066937A1 (en) * 2020-09-23 2022-03-31 Regents Of The University Of Minnesota Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use
KR102572595B1 (ko) * 2020-12-02 2023-08-31 충북대학교 산학협력단 불멸화 고양이줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR102456805B1 (ko) * 2020-12-02 2022-10-24 충북대학교 산학협력단 불멸화 개줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
CN112941033A (zh) * 2021-03-11 2021-06-11 深圳市人民医院 永生化饲养层细胞株的构建方法、永生化饲养层细胞株及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012314A1 (en) * 1996-09-17 1998-03-26 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
WO1999035243A2 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5919997A (en) * 1993-11-18 1999-07-06 Cold Spring Habor Labortary Transgenic mice having modified cell-cycle regulation
US5729597A (en) * 1995-05-16 1998-03-17 At&T Corp Service and information management system for a telecommunications network
US5629159A (en) * 1995-06-07 1997-05-13 California Institute Of Technology Immortalization and disimmortalization of cells
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2319238T3 (es) * 1996-07-01 2009-05-05 Gemin X Pharmaceuticals Canada Inc. Composiciones para modular la longitud de los talomeros.
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
ES2291025T3 (es) * 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012314A1 (en) * 1996-09-17 1998-03-26 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
WO1999035243A2 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796961B2 (en) 2005-10-18 2017-10-24 The Regents Of The University Of Colorado Conditionally immortalized long-term stem cells and methods of making and using such cells
JP2013017486A (ja) * 2005-10-18 2013-01-31 National Jewish Health 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2014158503A (ja) * 2005-10-18 2014-09-04 National Jewish Health 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US9150831B2 (en) 2005-10-18 2015-10-06 The Regents Of The University Of Colorado Conditionally immortalized long-term stem cells and methods of making and using such cells
US10760055B2 (en) 2005-10-18 2020-09-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
US11667695B2 (en) 2008-05-16 2023-06-06 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9428571B2 (en) 2008-05-16 2016-08-30 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US10442853B2 (en) 2008-05-16 2019-10-15 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9169462B2 (en) 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
JP2011528567A (ja) * 2008-07-21 2011-11-24 タイガ バイオテクノロジーズ，インク． 分化無核細胞、及び該無核細胞の作成方法
US11369678B2 (en) 2008-08-28 2022-06-28 Taiga Biotechnologies, Inc. Compositions and methods for modulating immune cells
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US12496341B2 (en) 2008-08-28 2025-12-16 Htyr Acquisition Llc Methods for reducing anergy in lymphocytes using modulators of MYC
US9775897B2 (en) 2008-08-28 2017-10-03 Taiga Biotechnologies, Inc. Modulators of MYC and methods of using the same
US10556006B2 (en) 2008-08-28 2020-02-11 Taiga Biotechnologies, Inc. Compositions and methods for modulating an immune response
US10953048B2 (en) 2012-07-20 2021-03-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10206952B2 (en) 2012-07-20 2019-02-19 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10786534B2 (en) 2013-03-11 2020-09-29 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10087420B2 (en) 2013-03-11 2018-10-02 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US12344658B2 (en) 2016-12-02 2025-07-01 HTYR Acquistion LLC Nanoparticle formulations
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
JPWO2022097716A1 (enExample) * 2020-11-06 2022-05-12
JP2026012286A (ja) * 2020-11-06 2026-01-23 株式会社Trans Chromosomics 可逆的不死化細胞の製造方法
JP7805590B2 (ja) 2020-11-06 2026-01-26 株式会社Trans Chromosomics 可逆的不死化細胞の製造方法

Also Published As

Publication number Publication date
EP1244798A2 (en) 2002-10-02
WO2001038548A2 (en) 2001-05-31
AU2667901A (en) 2001-06-04
CA2389667A1 (en) 2001-05-31
EP1103615A1 (en) 2001-05-30
WO2001038548A3 (en) 2001-10-18
US20090142841A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US20090142841A1 (en) Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
AU2018202200B2 (en) Improved gene therapy methods
Reiser et al. Development of multigene and regulated lentivirus vectors
CN100443593C (zh) 用病毒载体稳定转导细胞的方法
CA2328404C (en) Novel lentiviral packaging cells
CA2234931C (en) Novel expression vectors and methods of use
US5723333A (en) Human pancreatic cell lines: developments and uses
JP2002512804A (ja) ヌクレオチド配列の導入のためのトリプレックス構造のｄｎａ配列の利用
KR20000049250A (ko) 렌티바이러스 벡터
US6110743A (en) Development and use of human pancreatic cell lines
JP2020500562A (ja) ムコ多糖症ｉｉ型のための遺伝子治療
US20080124308A1 (en) Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins
JP6853538B2 (ja) 線維芽細胞からの心臓前駆細胞と心筋細胞の直接製造方法
JP2002526083A (ja) ポリヌクレオチド構築物およびその使用
KR20240099439A (ko) 코알라 레트로바이러스 외피 당단백질 및 그 용도
EP0808364B1 (en) Human pancreatic cell lines: developments and uses
WO2024149284A1 (en) Regulatory sequences and uses thereof
US20030202967A1 (en) Development and use of human pancreatic cell lines
NZ503827A (en) Suspension packing cell lines for retrovirus vectors
WO2025157808A1 (fr) Production de vecteurs toxiques
WO2002094989A2 (en) Retroviral vectors and methods of using same
MXPA97006019A (en) Human pancreatic cellular lines: developments and u
Logan Leukemia cell vaccine generation using lentiviral vectors
HK1149289A (en) Use of lentiviral triplex forming sequences for nuclear transfer of nucleotide sequences
HK1034283B (en) Use of triplex structure dna sequences for transferring nucleotide sequences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308